Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome) | MicrobiomeTrials
Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-05-31Est. Completion: 2028-01-31
Enrollment target: 636 participants
Locations
Beijing Hospital of Traditional Chinese Medicine, Beijing, Dongcheng District, China
West China Hospital, Sichuan University, Chengdu, China
Chongqing Traditional Chinese Medicine Hospital, Chongqing, China
The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guizhou, China
Haozhou People's Hospital, Haozhou, China
Hebei Provincial Hospital of Traditional Chinese Medicine, Hebei, China
The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Heilongjiang, China
Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei, China
The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
Kaifeng Hospital of Traditional Chinese Medicine, Kaifeng, China
Luoyang First People's Hospital, Luoyang, China
Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, China
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
Other microbiome trials you might be interested in